TULSA Procedure Shows Superiority Over Robotic Prostatectomy in Key Safety Trial
Summary
Profound Medical Corp.'s TULSA Procedure demonstrated statistical superiority over robotic radical prostatectomy (RP) in the CAPTAIN randomized controlled trial's primary safety endpoint. The trial showed significantly better preservation of erectile function and urinary continence at 6 months for TULSA patients (50% vs. 24% for RP). Additionally, TULSA exhibited favorable quality-of-life outcomes, reduced perioperative measures like blood loss and hospital stay, and a lower rate of serious complications compared to RP. These strong functional and safety results from a head-to-head trial against a standard treatment are a major positive catalyst, potentially driving significant adoption and market share for Profound's MRI-guided therapy. Investors will now watch for the secondary oncologic outcomes, expected later this year.
At the time of this announcement, PROF was trading at $5.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212M. The 52-week trading range was $3.76 to $8.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.